The International Society for Cell & Gene Therapy (ISCT) is seeking an Editor in Chief (EiC) for the Society’s official peer-reviewed journal, Cytotherapy. This new leadership position is anticipated to begin October, 2023.
The journal publishes novel and innovative results from high-quality scientific, translational, and clinical studies in the fields of cell and gene therapy. In addition to short reports and full-length articles, the journal also accepts editorials on emerging trends and potential controversies in the field, and review articles summarizing important areas of cell and gene therapy research that are topical and/or challenge existing paradigms in the field.
The EiC is the principal architect of the Journal. The role involves strategic oversight of the entire editorial process, from manuscript submission to publication, and includes strategic planning for the journal's growth and development by setting the strategic direction and scope of Cytotherapy. As an Ex Officio Director, the EiC will serve on the Society’s Board of Directors, report to the ISCT Publications Committee regularly, and engage actively with the scientific community, both within and outside of ISCT. The EiC is responsible for leading the Editorial Board, promoting the journal, maintaining relationships with key stakeholders, implementing editorial policies and guidelines, managing peer reviews, ensuring quality assurance, handling complaints, and ensuring timely publication. This position is highly visible within the cell and gene therapy community. The successful candidate will be a visionary for the journal grounded in a strong understanding of where the cell and gene therapy field is currently, where it is heading, and connections with related areas of science, technology, and medicine. The candidate selected will assess the needs of authors, readers, and reviewers and provide sustained value in the changing world of science and publishing.
This editorial position requires an individual with energy and vision to sustain and further develop this journal. This is a compensated position.
Applicants are to email their curriculum vitae, a list of publications and a letter of intent by July 15, 2023, to the attention of Queenie Jang, ISCT Chief Executive Officer, as listed below. The letter of intent should include: an assessment of the strengths and weaknesses of Cytotherapy, your relevant experience and expertise, a vision for the journal’s future, and your ability to fulfill the time commitments required by this role.
To the attention of:
Queenie Jang, BSc (Pharmacy), MBA
Chief Executive Officer
International Society for Cell & Gene Therapy
View Full Job Description
© 2021 ISCT. All rights reserved.
Site by eConverse Media